152 related articles for article (PubMed ID: 29890238)
21. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
Stone RM; Manley PW; Larson RA; Capdeville R
Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
[TBL] [Abstract][Full Text] [Related]
22. Midostaurin for the treatment of acute myeloid leukemia.
Patnaik MM
Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic KIT D816Y mutation presenting as in utero aggressive systemic mastocytosis with response to midostaurin.
Voelker D; Bednarski JJ; Nieman E; Carter MC; Polk B
J Allergy Clin Immunol Pract; 2023 Apr; 11(4):1323-1325.e1. PubMed ID: 36581075
[No Abstract] [Full Text] [Related]
24. Midostaurin in Advanced Systemic Mastocytosis: A Systematic Review and Meta-analysis.
Abuhelwa Z; Beran A; Kahlon N; Sayeh W; Khokher W; Assaly R; Hamouda DM
Am J Ther; 2023 Nov-Dec 01; 30(6):e573-e575. PubMed ID: 35446286
[No Abstract] [Full Text] [Related]
25. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
[TBL] [Abstract][Full Text] [Related]
26. [Systemic mastocytosis].
Metzgeroth G; Schwaab J; Reiter A
Dtsch Med Wochenschr; 2014 Aug; 139(31-32):1572-5. PubMed ID: 25076308
[No Abstract] [Full Text] [Related]
27. Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
Pilkington H; Smith S; Roskell N; Iannazzo S
Future Oncol; 2022 Apr; 18(13):1583-1594. PubMed ID: 35114819
[TBL] [Abstract][Full Text] [Related]
28. Midostaurin in FLT3-mutated acute myeloid leukaemia.
Das M
Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
[No Abstract] [Full Text] [Related]
29. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
[No Abstract] [Full Text] [Related]
30. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.
Gotlib J
Hematol Oncol Clin North Am; 2017 Aug; 31(4):643-661. PubMed ID: 28673393
[TBL] [Abstract][Full Text] [Related]
32. Avapritinib in the Treatment of Systemic Mastocytosis: an Update.
Below S; Michaelis LC
Curr Hematol Malig Rep; 2021 Oct; 16(5):464-472. PubMed ID: 34580817
[TBL] [Abstract][Full Text] [Related]
33. Interactive medical case. A rash hypothesis.
Ross JJ; Saavedra A; Vleugels RA; Liu A; Castells MC
N Engl J Med; 2010 Jun; 362(24):e69. PubMed ID: 20560180
[No Abstract] [Full Text] [Related]
34. Novel Approaches for Systemic Mastocytosis.
Fletcher L; Borate U
Curr Opin Hematol; 2019 Mar; 26(2):112-118. PubMed ID: 30694839
[TBL] [Abstract][Full Text] [Related]
35. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
37. [Systemic mastocytosis].
Sökler M; Kanz L
Dtsch Med Wochenschr; 2005 Mar; 130(9):474. PubMed ID: 15731964
[No Abstract] [Full Text] [Related]
38. Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis.
Broderick V; Waghorn K; Langabeer SE; Jeffers M; Cross NCP; Hayden PJ
Leuk Res; 2019 Feb; 77():28-29. PubMed ID: 30612056
[No Abstract] [Full Text] [Related]
39. Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies
Manley PW; Weisberg E; Sattler M; Griffin JD
Biochemistry; 2018 Feb; 57(5):477-478. PubMed ID: 29188995
[No Abstract] [Full Text] [Related]
40. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
